MedTrace Logo

A Novel Iron Supplement for Athletes: Phase I

NCT06285851 · Status: COMPLETED · Phase: NA · Type: INTERVENTIONAL · Enrollment: 14

Last updated 2024-03-28

No results posted yet for this study

Summary

Female endurance athletes are susceptible to iron deficiency and this can impact their exercise performance. This study is a pilot trial to assess the tolerability of a novel iron supplement prior to conducting a clinical trial on the efficacy of the developed novel iron supplement on iron status and performance.

Conditions

Interventions

DIETARY_SUPPLEMENT

FeSC

Supplement

Sponsors & Collaborators

  • Lallemand Bio-Ingredients

    collaborator OTHER

  • University of Calgary

    lead OTHER

Principal Investigators

  • Jane Shearer, PhD · University of Calgary

Study Design

Allocation
NA
Purpose
OTHER
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
18 Years
Max Age
25 Years
Sex
FEMALE
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2023-11-23
Primary Completion
2023-12-12
Completion
2023-12-12

Countries

  • Canada

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT06285851 on ClinicalTrials.gov